trending Market Intelligence /marketintelligence/en/news-insights/trending/nX_24498_lIqHG7h7bqzuA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Momenta Pharmaceuticals to raise up to $230M from common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Momenta Pharmaceuticals to raise up to $230M from common stock offering

Momenta Pharmaceuticals Inc. priced an underwritten public offering of its common stock to raise up to $230 million in gross proceeds.

The Cambridge, Mass.-based biotechnology company is offering $200 million worth of its shares. Underwriters will also receive an option to buy up to an additional $30 million of the company's common stock.

Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint lead book-running managers for the offering, while Stifel is acting as a book-running manager.